MedMira Inc. (MIR.V)
CAD 0.08
(-5.88%)
CAD 0.08
(-5.88%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.95 Million CAD | 44.41% |
| 2022 | 2.04 Million CAD | -6.89% |
| 2021 | 2.19 Million CAD | -30.22% |
| 2020 | 3.15 Million CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | -100.0% |
| 2017 | 237.49 Thousand CAD | -6.89% |
| 2016 | 255.06 Thousand CAD | -88.59% |
| 2015 | 2.23 Million CAD | -43.93% |
| 2014 | 3.98 Million CAD | -14.89% |
| 2013 | 4.68 Million CAD | 1956.02% |
| 2012 | 227.8 Thousand CAD | 0.0% |
| 2011 | - CAD | -100.0% |
| 2010 | 430.32 Thousand CAD | -54.05% |
| 2009 | 936.56 Thousand CAD | -15.55% |
| 2008 | 1.1 Million CAD | 3.25% |
| 2007 | 1.07 Million CAD | -27.11% |
| 2006 | 1.47 Million CAD | 57.99% |
| 2005 | 932.65 Thousand CAD | -42.42% |
| 2004 | 1.61 Million CAD | 159.14% |
| 2003 | 625 Thousand CAD | -92.65% |
| 2002 | 8.5 Million CAD | 0.0% |
| 2001 | - CAD | -100.0% |
| 2000 | 87.49 Thousand CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 885.71 Thousand CAD | -21.93% |
| 2024 Q1 | 2.93 Million CAD | 1.42% |
| 2024 Q3 | 862.73 Thousand CAD | -2.59% |
| 2023 Q2 | 2.57 Million CAD | 8.41% |
| 2023 FY | 2.95 Million CAD | 44.41% |
| 2023 Q1 | 2.37 Million CAD | 15.85% |
| 2023 Q4 | 2.95 Million CAD | -1.82% |
| 2023 Q3 | 3.01 Million CAD | 17.11% |
| 2022 Q2 | 2.13 Million CAD | -1.91% |
| 2022 Q4 | 2.04 Million CAD | -1.98% |
| 2022 Q1 | 2.17 Million CAD | -1.24% |
| 2022 FY | 2.04 Million CAD | -6.89% |
| 2022 Q3 | 2.08 Million CAD | -1.94% |
| 2021 Q1 | 3.1 Million CAD | -1.41% |
| 2021 Q2 | 2.48 Million CAD | -20.07% |
| 2021 FY | 2.19 Million CAD | -30.22% |
| 2021 Q3 | 2.23 Million CAD | -9.87% |
| 2021 Q4 | 2.19 Million CAD | -1.77% |
| 2020 Q1 | 2.41 Million CAD | 0.0% |
| 2020 Q2 | 2.37 Million CAD | -1.57% |
| 2020 Q3 | 2.38 Million CAD | 0.09% |
| 2020 Q4 | 3.15 Million CAD | 32.35% |
| 2020 FY | 3.15 Million CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 FY | - CAD | -100.0% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2017 Q4 | 237.49 Thousand CAD | -65.49% |
| 2017 Q2 | 285.92 Thousand CAD | 0.0% |
| 2017 Q1 | - CAD | -100.0% |
| 2017 Q3 | 688.12 Thousand CAD | 140.66% |
| 2017 FY | 237.49 Thousand CAD | -6.89% |
| 2016 Q4 | 255.06 Thousand CAD | -86.86% |
| 2016 FY | 255.06 Thousand CAD | -88.59% |
| 2016 Q3 | 1.94 Million CAD | -44.42% |
| 2016 Q2 | 3.49 Million CAD | -15.87% |
| 2016 Q1 | 4.15 Million CAD | 85.77% |
| 2015 FY | 2.23 Million CAD | -43.93% |
| 2015 Q3 | 2.39 Million CAD | -17.45% |
| 2015 Q4 | 2.23 Million CAD | -6.62% |
| 2015 Q1 | 3 Million CAD | -24.6% |
| 2015 Q2 | 2.89 Million CAD | -3.53% |
| 2014 Q4 | 3.98 Million CAD | -2.26% |
| 2014 Q1 | 4.48 Million CAD | -4.14% |
| 2014 FY | 3.98 Million CAD | -14.89% |
| 2014 Q2 | 4.33 Million CAD | -3.47% |
| 2014 Q3 | 4.07 Million CAD | -5.9% |
| 2013 Q3 | 5.04 Million CAD | -4.43% |
| 2013 Q1 | 7.37 Million CAD | 3137.51% |
| 2013 FY | 4.68 Million CAD | 1956.02% |
| 2013 Q4 | 4.68 Million CAD | -7.19% |
| 2013 Q2 | 5.28 Million CAD | -28.4% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | 227.8 Thousand CAD | 0.0% |
| 2012 Q4 | 227.8 Thousand CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | -100.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | -100.0% |
| 2010 FY | 430.32 Thousand CAD | -54.05% |
| 2010 Q1 | - CAD | -100.0% |
| 2010 Q2 | 4.48 Million CAD | 0.0% |
| 2010 Q3 | 4.37 Million CAD | -2.39% |
| 2010 Q4 | 430.32 Thousand CAD | -90.16% |
| 2009 Q1 | 1.59 Million CAD | 43.59% |
| 2009 Q2 | 1.56 Million CAD | -1.44% |
| 2009 Q3 | 1.2 Million CAD | -23.51% |
| 2009 Q4 | 936.56 Thousand CAD | -21.99% |
| 2009 FY | 936.56 Thousand CAD | -15.55% |
| 2008 Q1 | 1.13 Million CAD | 5.44% |
| 2008 FY | 1.1 Million CAD | 3.25% |
| 2008 Q4 | 1.1 Million CAD | -67.44% |
| 2008 Q3 | 3.4 Million CAD | 185.25% |
| 2008 Q2 | 1.19 Million CAD | 5.43% |
| 2007 FY | 1.07 Million CAD | -27.11% |
| 2007 Q1 | 13.13 Million CAD | 791.09% |
| 2007 Q3 | 968.89 Thousand CAD | -6.24% |
| 2007 Q4 | 1.07 Million CAD | 10.85% |
| 2007 Q2 | 1.03 Million CAD | -92.13% |
| 2006 FY | 1.47 Million CAD | 57.99% |
| 2006 Q4 | 1.47 Million CAD | -26.42% |
| 2006 Q3 | 2 Million CAD | -7.41% |
| 2006 Q1 | 733.33 Thousand CAD | -21.37% |
| 2006 Q2 | 2.16 Million CAD | 194.95% |
| 2005 Q4 | 932.65 Thousand CAD | -60.06% |
| 2005 FY | 932.65 Thousand CAD | -42.42% |
| 2005 Q1 | 2.76 Million CAD | 70.84% |
| 2005 Q2 | 2.44 Million CAD | -11.74% |
| 2005 Q3 | 2.33 Million CAD | -4.37% |
| 2004 Q1 | 625 Thousand CAD | 0.0% |
| 2004 FY | 1.61 Million CAD | 159.14% |
| 2004 Q3 | 655.1 Thousand CAD | 0.0% |
| 2004 Q4 | 1.61 Million CAD | 147.23% |
| 2004 Q2 | 655.1 Thousand CAD | 4.82% |
| 2003 Q3 | 8.5 Million CAD | -0.47% |
| 2003 Q1 | 8.55 Million CAD | 0.6% |
| 2003 FY | 625 Thousand CAD | -92.65% |
| 2003 Q2 | 8.54 Million CAD | -0.13% |
| 2003 Q4 | 625 Thousand CAD | -92.65% |
| 2002 Q3 | - CAD | -100.0% |
| 2002 FY | 8.5 Million CAD | 0.0% |
| 2002 Q2 | 760.91 Thousand CAD | 162.39% |
| 2002 Q4 | 8.5 Million CAD | 0.0% |
| 2002 Q1 | 290 Thousand CAD | 0.0% |
| 2001 FY | - CAD | -100.0% |
| 2000 FY | 87.49 Thousand CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 703.92 Thousand CAD | -320.108% |
| Covalon Technologies Ltd. | 919.08 Thousand CAD | -221.76% |
| Hemostemix Inc. | 4.32 Million CAD | 31.569% |
| Universal Ibogaine Inc. | 1.73 Million CAD | -70.183% |
| Kane Biotech Inc. | 1.3 Million CAD | -127.049% |
| Marvel Biosciences Corp. | 1 Million CAD | -195.723% |
| NervGen Pharma Corp. | 105.6 Thousand CAD | -2700.299% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |